Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Development of ALL-Hematotox (ALL-HT): Predicting post CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia

Monica S Nair, Sara K Silbert, Kai Rejeski, Karilynn A Wilson, Adam Joseph Lamble, Yannis K. Valtis, Bonnie Yates, Alexa Morales Arana, Roni Shouval, Kevin J. Curran, Rebecca A Gardner, Haneen Shalabi, Colleen Annesley, Jae H. Park, Marion Subklewe, Nirali N Shah

Blood blood.2024025910.

https://doi.org/10.1182/blood.2024025910

Published: 2024

Includes: Supplemental data

Journal Articles

Clinical Factors Associated with Prolonged Cytopenias after CD19 Chimeric Antigen Receptor T-Cell Therapy for Pediatric B-Cell Acute Lymphoblastic Leukemia

Regina M. Myers, Yimei Li, Adam Lamble, Emily M. Hsieh, Samuel John, Gregory Dolan, Hongyan Liu, Lee Chen, Jennifer Sheppard, Amanda M. DiNofia, Colleen Annesley, Stephan A. Grupp, Deepa Bhojwani, Rebecca A. Gardner, Lia Gore, Susan R Rheingold, Nirali N. Shah, Michael A. Pulsipher

Blood (2024) 144 (Supplement 1): 4827.

https://doi.org/10.1182/blood-2024-202027

Published: 2024

Journal Articles

A Phase 2 Trial of SCRI-CAR19 Demonstrates Favorable Leukemia-Free Survival (LFS), with a Pilot Study of CD19-Expressing T-Cell Antigen Presenting Cells (CD19t T-APCs) Demonstrating Safety and Tolerability

Colleen Annesley, Kristy Seidel, Qian Vicky Wu, Corinne Summers, Alan S. Wayne, Anurag K. Agrawal, Michael A. Pulsipher, Christopher Brown, Stephanie Mgebroff, Catherine Lindgren, Ashley L. Wilson, Wenjun Huang, Julie R. Park, Michael C. Jensen, Rebecca A. Gardner

Blood (2023) 142 (Supplement 1): 3467.

https://doi.org/10.1182/blood-2023-190525

Published: 2023

Journal Articles

Impact of Hematopoietic Cell Transplantation after CAR T-Cell Therapy for B-ALL: Comparison of Statistical Models and Survival Curves By a Novel R Shiny Tool

Yimei Li, Yang Qiao, Jordan Gauthier, Qiang Zhang, Jenna M. Voutsinas, Wendy Leisenring, Ted A. Gooley, Corinne Summers, Alexandre Vinaud Hirayama, Cameron J. Turtle, Rebecca A Gardner, Qian Vicky Wu

Blood (2022) 140 (Supplement 1): 12947–12949.

https://doi.org/10.1182/blood-2022-167264

Published: 2022

Journal Articles

In Vivo PBMC-Humanized Mouse Model to Assess Individual Variability in Efficacy and Toxicity of Autologous and Allogeneic Chimeric Antigen Receptor T-Cell Immunotherapy

Won Lee, Destanie Rose, Mingshan Cheng, Heather Gustafson, Rebecca A Gardner, James G Keck, Jiwon Yang

Blood (2022) 140 (Supplement 1): 10267–10268.

https://doi.org/10.1182/blood-2022-158057

Published: 2022

Journal Articles

Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells

Blood (2021) 138 (24): 2469–2484.

https://doi.org/10.1182/blood.2021011898

Published: 2021

Includes: Supplemental data

Journal Articles

Poor Clinical Outcome in Pediatric Immunotherapy Is Mediated By a Pre-Existing Overactive IL-18-IFNy Immune Phenotype

Katelyn Burleigh, Anna Kus, Alice Long, Michael C. Jensen, Seth Masters, James E Vince, Bobbie-Jo Webb-Robertson, Rebecca A Gardner, Heather Gustafson

Blood (2021) 138 (Supplement 1): 168.

https://doi.org/10.1182/blood-2021-148013

Published: 2021

Journal Articles

SCRI-CAR19x22v2 T Cell Product Demonstrates Bispecific Activity in B-ALL

Colleen Annesley, Corinne Summers, Michael A. Pulsipher, Jodi L. Skiles, Amanda M. Li, Anant Vatsayan, Catherine Lindgren, Stephanie Mgebroff, Ashley Wilson, Wenjun Huang, Qian Vicky Wu, Josh Gustafson, Christopher Brown, Michael C. Jensen, Julie R. Park, Rebecca A Gardner

Blood (2021) 138 (Supplement 1): 470.

https://doi.org/10.1182/blood-2021-148881

Published: 2021

Journal Articles

CD22 CAR Optimization for Improved in-Human Activity Following Inadequate CD22 CAR Activity in Phase 1 Clinical Trial PLAT-04

Corinne Summers, Blake Baxter, Colleen Annesley, Jason Yokoyama, Stephanie Rhea, Wenjun Huang, Ashley Wilson, Julie R. Park, Rimas J Orentas, Michael C. Jensen, Rebecca A Gardner

Blood (2021) 138 (Supplement 1): 403.

https://doi.org/10.1182/blood-2021-147928

Published: 2021

Journal Articles

KMT2A Rearrangements Are Associated with Lineage Switch Following CD19 Targeting CAR T-Cell Therapy

Blood (2021) 138 (Supplement 1): 256.

https://doi.org/10.1182/blood-2021-153336

Published: 2021

Journal Articles

Pre-CAR Blinatumomab Is Associated with Increased Post-CD19 CAR Relapse and Decreased Event Free Survival

Agne Taraseviciute, MD, Seth M. Steinberg, PhD, Regina M. Myers, MD, Lia Gore, MD, Adam J. Lamble, MD, Patrick A. Brown, MD, Jennifer Sheppard, Bonnie Yates, NP, Perry Chung, MD, Lee Chen, Colleen Annesley, MD, Deepa Bhojwani, MD, Theodore W. Laetsch, MD, Rebecca A Gardner, MD, Susan R. Rheingold, MD, Michael A Pulsipher, MD, Nirali N. Shah, MD

Blood (2020) 136 (Supplement 1): 13–14.

https://doi.org/10.1182/blood-2020-139260

Published: 2020

Journal Articles

Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy

Rebecca A. Gardner, Francesco Ceppi, Julie Rivers, Colleen Annesley, Corinne Summers, Agne Taraseviciute, Juliane Gust, Kasey J. Leger, Katherine Tarlock, Todd M. Cooper, Olivia C. Finney, Hannah Brakke, Daniel H. Li, Julie R. Park, Michael C. Jensen

Blood (2019) 134 (24): 2149–2158.

https://doi.org/10.1182/blood.2019001463

Published: 2019

Includes: Supplemental data

Journal Articles

Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults

Rebecca A. Gardner, Olivia Finney, Colleen Annesley, Hannah Brakke, Corinne Summers, Kasey Leger, Marie Bleakley, Christopher Brown, Stephanie Mgebroff, Karen S. Kelly-Spratt, Virginia Hoglund, Catherine Lindgren, Assaf P. Oron, Daniel Li, Stanley R. Riddell, Julie R. Park, Michael C. Jensen

Blood (2017) 129 (25): 3322–3331.

https://doi.org/10.1182/blood-2017-02-769208

Published: 2017

Includes: Supplemental data

Journal Articles

Nelarabine in Combination with Etoposide and Cyclophosphamide Is Active in First Relapse of Childhood T-Acute Lymphocytic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LL)

Blood (2014) 124 (21): 795.

https://doi.org/10.1182/blood.V124.21.795.795

Published: 2014

Journal Articles

T Cell Products of Defined CD4:CD8 Composition and Prescribed Levels of CD19CAR/Egfrt Transgene Expression Mediate Regression of Acute Lymphoblastic Leukemia in the Setting of Post-Allohsct Relapse

Rebecca A Gardner, MD, Julie R Park, MD, Karen S Kelly-Spratt, PhD, Olivia Finney, PhD, Hannah Smithers, Virginia Hoglund, Christopher Brown, Stephanie Mgebroff, MS, Catherine G. Lindgren, Assaf P Oron, PhD, Marie Bleakley, MD, Michael C Jensen, MD

Blood (2014) 124 (21): 3711.

https://doi.org/10.1182/blood.V124.21.3711.3711

Published: 2014

Journal Articles

A Phase I Dose Finding Study of Panobinostat in Children with Hematologic Malignancies: Initial Report of TACL Study T2009-012 in Children with Acute Leukemia

Blood (2014) 124 (21): 3705.

https://doi.org/10.1182/blood.V124.21.3705.3705

Published: 2014

Journal Articles

The UK ALLR3 Chemotherapy Regimen for Relapsed/Refractory Acute Lymphoblastic Leukemia of Childhood: A Multi-Institutional Retrospective Study of Treatment Related Adverse Events

Weili Sun, MDPhD, Alison Marie Smith, BS, Orgal Etan, MD, Richard Sposto, PhD, Jennifer J. Wilkes, MD, Rebecca A Gardner, MD, Hur Minjun, Vanessa Pineros, Emily Olson, MD, Yijuin Tan, Susan R. Rheingold, MD, Michael J. Burke, MD, Alan S. Wayne, MD

Blood (2014) 124 (21): 3647.

https://doi.org/10.1182/blood.V124.21.3647.3647

Published: 2014

Journal Articles

Generation of CD19-chimeric antigen receptor modified CD8 + T cells derived from virus-specific central memory T cells

Seitaro Terakura, Tori N. Yamamoto, Rebecca A. Gardner, Cameron J. Turtle, Michael C. Jensen, Stanley R. Riddell

Blood (2012) 119 (1): 72–82.

https://doi.org/10.1182/blood-2011-07-366419

Published: 2012

Includes: Supplemental data

Journal Articles

Generation and Signaling Function of CD19 Chimeric Antigen Receptor Modified CD8 + T Cells Derived From Virus-Specific Central Memory Cells for Adoptive Therapy After Allogeneic Hematopoietic Stem Cell Transplant

Seitaro Terakura, MD, PhD, Tori N. Yamamoto, Rebecca A. Gardner, MD, Cameron J. Turtle, MBBS, PhD, Michael C. Jensen, MD, Stanley R. Riddell, MD

Blood (2011) 118 (21): 2978.

https://doi.org/10.1182/blood.V118.21.2978.2978

Published: 2011

NARROW

Development of ALL-Hematotox (ALL-HT): Predicting post CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia

Clinical Factors Associated with Prolonged Cytopenias after CD19 Chimeric Antigen Receptor T-Cell Therapy for Pediatric B-Cell Acute Lymphoblastic Leukemia

A Phase 2 Trial of SCRI-CAR19 Demonstrates Favorable Leukemia-Free Survival (LFS), with a Pilot Study of CD19-Expressing T-Cell Antigen Presenting Cells (CD19t T-APCs) Demonstrating Safety and Tolerability

Impact of Hematopoietic Cell Transplantation after CAR T-Cell Therapy for B-ALL: Comparison of Statistical Models and Survival Curves By a Novel R Shiny Tool

In Vivo PBMC-Humanized Mouse Model to Assess Individual Variability in Efficacy and Toxicity of Autologous and Allogeneic Chimeric Antigen Receptor T-Cell Immunotherapy

Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells

Poor Clinical Outcome in Pediatric Immunotherapy Is Mediated By a Pre-Existing Overactive IL-18-IFNy Immune Phenotype

SCRI-CAR19x22v2 T Cell Product Demonstrates Bispecific Activity in B-ALL

CD22 CAR Optimization for Improved in-Human Activity Following Inadequate CD22 CAR Activity in Phase 1 Clinical Trial PLAT-04

KMT2A Rearrangements Are Associated with Lineage Switch Following CD19 Targeting CAR T-Cell Therapy

Pre-CAR Blinatumomab Is Associated with Increased Post-CD19 CAR Relapse and Decreased Event Free Survival

Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy

Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults

Nelarabine in Combination with Etoposide and Cyclophosphamide Is Active in First Relapse of Childhood T-Acute Lymphocytic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LL)

T Cell Products of Defined CD4:CD8 Composition and Prescribed Levels of CD19CAR/Egfrt Transgene Expression Mediate Regression of Acute Lymphoblastic Leukemia in the Setting of Post-Allohsct Relapse

A Phase I Dose Finding Study of Panobinostat in Children with Hematologic Malignancies: Initial Report of TACL Study T2009-012 in Children with Acute Leukemia

The UK ALLR3 Chemotherapy Regimen for Relapsed/Refractory Acute Lymphoblastic Leukemia of Childhood: A Multi-Institutional Retrospective Study of Treatment Related Adverse Events

Generation of CD19-chimeric antigen receptor modified CD8 + T cells derived from virus-specific central memory T cells

Generation and Signaling Function of CD19 Chimeric Antigen Receptor Modified CD8 + T Cells Derived From Virus-Specific Central Memory Cells for Adoptive Therapy After Allogeneic Hematopoietic Stem Cell Transplant

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only